The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

Drs Ursula A. Matulonis and Gini F. Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field.